

Claudia Hube-Magg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1217346/publications.pdf>

Version: 2024-02-01

109
papers

1,961
citations

279798

23
h-index

377865

34
g-index

110
all docs

110
docs citations

110
times ranked

3230
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. <i>Cancer Cell</i> , 2018, 34, 996-1011.e8.	16.8	190
2	Random forest-based modelling to detect biomarkers for prostate cancer progression. <i>Clinical Epigenetics</i> , 2019, 11, 148.	4.1	89
3	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. <i>Neoplasia</i> , 2017, 19, 707-715.	5.3	65
4	Prevalence of β -tubulin (TUBB3) expression in human normal tissues and cancers. <i>Tumor Biology</i> , 2017, 39, 101042831771216.	1.8	51
5	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. <i>Oncotarget</i> , 2015, 6, 8377-8387.	1.8	44
6	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 3471-3479.	7.0	43
7	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. <i>Biomedicines</i> , 2021, 9, 397.	3.2	42
8	Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. <i>Disease Markers</i> , 2019, 2019, 1-11.	1.3	38
9	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. <i>European Journal of Cancer</i> , 2014, 50, 852-861.	2.8	34
10	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. <i>Oncotarget</i> , 2015, 6, 12822-12834.	1.8	34
11	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. <i>Biomarker Research</i> , 2021, 9, 7.	6.8	33
12	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. <i>Aging</i> , 2019, 11, 7796-7804.	3.1	33
13	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. <i>Molecular Medicine</i> , 2021, 27, 16.	4.4	32
14	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SEN1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. <i>BMC Cancer</i> , 2015, 15, 538.	2.6	30
15	Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers. <i>International Journal of Cancer</i> , 2016, 138, 1199-1206.	5.1	30
16	High-Level β -Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2017, 18, 286.	4.1	30
17	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. <i>Biomarker Research</i> , 2021, 9, 44.	6.8	30
18	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , 2015, 6, 27966-27979.	1.8	30

#	ARTICLE	IF	CITATIONS
19	Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma. <i>BMC Cancer</i> , 2018, 18, 1209.	2.6	28
20	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. <i>Aging</i> , 2019, 11, 7859-7879.	3.1	28
21	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. <i>Prostate</i> , 2016, 76, 259-272.	2.3	27
22	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. <i>PLoS ONE</i> , 2015, 10, e0128525.	2.5	26
23	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. <i>Experimental and Molecular Pathology</i> , 2015, 98, 419-426.	2.1	26
24	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 877-882.	2.2	26
25	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. <i>Oncotarget</i> , 2017, 8, 108923-108935.	1.8	26
26	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. <i>BMC Cancer</i> , 2019, 19, 193.	2.6	24
27	High homogeneity of MMR deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 156, 669-675.	1.4	24
28	Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 421-430.	4.4	23
29	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. <i>Oncotarget</i> , 2019, 10, 5439-5453.	1.8	22
30	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. <i>Tumor Biology</i> , 2016, 37, 12655-12663.	1.8	20
31	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3997-4006.	1.5	20
32	Apurinic/apyrimidinic endonuclease 1 (APE1/Ref1) overexpression is an independent prognostic marker in prostate cancer without <i>TMPRSS2:ERG</i> fusion. <i>Molecular Carcinogenesis</i> , 2017, 56, 2135-2145.	2.7	19
33	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. <i>BMC Cancer</i> , 2018, 18, 612.	2.6	19
34	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. <i>Oncology Letters</i> , 2019, 17, 3826-3834.	1.8	19
35	Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer. <i>Molecular Oncology</i> , 2020, 14, 129-138.	4.6	19
36	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 488-495.	1.6	19

#	ARTICLE	IF	CITATIONS
37	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. <i>Human Pathology</i> , 2021, 115, 19-36.	2.0	19
38	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. <i>Oncotarget</i> , 2020, 11, 237-249.	1.8	19
39	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. <i>Human Pathology</i> , 2016, 48, 102-110.	2.0	18
40	Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas. <i>American Journal of Surgical Pathology</i> , 2022, 46, 97-104.	3.7	18
41	Upregulation of centromere protein F is linked to aggressive prostate cancers. <i>Cancer Management and Research</i> , 2018, Volume 10, 5491-5504.	1.9	17
42	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 531.e19-531.e25.	1.6	17
43	High homogeneity of mismatch repair deficiency in advanced prostate cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 745-752.	2.8	17
44	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. <i>PLoS ONE</i> , 2015, 10, e0134614.	2.5	16
45	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. <i>Neoplasia</i> , 2017, 19, 279-287.	5.3	16
46	High-Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. <i>Prostate</i> , 2017, 77, 1528-1538.	2.3	16
47	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. <i>BMC Cancer</i> , 2018, 18, 37.	2.6	16
48	High B7â€³ expression is linked to increased risk of prostate cancer progression. <i>Pathology International</i> , 2020, 70, 733-742.	1.3	16
49	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. <i>Carcinogenesis</i> , 2017, 38, 1180-1187.	2.8	15
50	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. <i>Endocrine Pathology</i> , 2020, 31, 182-189.	9.0	15
51	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. <i>Experimental and Molecular Pathology</i> , 2022, 126, 104762.	2.1	15
52	Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. <i>Pathobiology</i> , 2022, 89, 245-258.	3.8	15
53	A shift from membranous and stromal syndecanâ€²1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. <i>Molecular Carcinogenesis</i> , 2019, 58, 2306-2315.	2.7	14
54	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. <i>Oncotarget</i> , 2020, 11, 1007-1016.	1.8	14

#	ARTICLE	IF	CITATIONS
55	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. <i>Cancer Biology and Medicine</i> , 2021, 18, 245-255.	3.0	13
56	Y-chromosome loss is frequent in male renal tumors. <i>Annals of Translational Medicine</i> , 2021, 9, 209-209.	1.7	13
57	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. <i>Oncology Reports</i> , 2015, 34, 1211-1220.	2.6	12
58	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. <i>BMC Cancer</i> , 2020, 20, 1220.	2.6	12
59	Napsin A Expression in Human Tumors and Normal Tissues. <i>Pathology and Oncology Research</i> , 2021, 27, 613099.	1.9	12
60	Pattern of placental alkaline phosphatase (<sc>PLAP</sc>) expression in human tumors: a tissue microarray study on 12,381 tumors. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 577-589.	3.0	12
61	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 481-490.	2.2	11
62	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naïve clear cell renal cell cancer. <i>International Urology and Nephrology</i> , 2021, 53, 2493-2503.	1.4	11
63	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 433-447.	2.8	11
64	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. <i>Annals of Diagnostic Pathology</i> , 2021, 54, 151793.	1.3	11
65	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. <i>Pathology Research and Practice</i> , 2021, 228, 153663.	2.3	11
66	Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers. <i>Human Pathology</i> , 2015, 46, 514-523.	2.0	10
67	High expression of class III β -tubulin in upper gastrointestinal cancer types. <i>Oncology Letters</i> , 2018, 16, 7139-7145.	1.8	10
68	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. <i>World Journal of Urology</i> , 2020, 38, 2185-2196.	2.2	10
69	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer. <i>Prostate</i> , 2020, 80, 1097-1107.	2.3	10
70	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10...399 Tissue Samples. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110433.	1.9	10
71	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. <i>Acta Oncologica</i> , 2021, 60, 1210-1217.	1.8	10
72	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. <i>Oncotarget</i> , 2017, 8, 31494-31508.	1.8	10

#	ARTICLE	IF	CITATIONS
73	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. <i>BMC Cancer</i> , 2017, 17, 504.	2.6	9
74	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. <i>Tumor Biology</i> , 2019, 41, 101042831882481.	1.8	9
75	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. <i>Medical Molecular Morphology</i> , 2021, 54, 156-165.	1.0	9
76	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. <i>Oncology Letters</i> , 2019, 18, 5107-5118.	1.8	9
77	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 43.e13-43.e20.	1.6	8
78	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. <i>Pathology International</i> , 2020, 70, 441-451.	1.3	8
79	Expression of the immune checkpoint receptor TIGIT in seminoma. <i>Oncology Letters</i> , 2019, 18, 1497-1502.	1.8	7
80	SNW1 is a prognostic biomarker in prostate cancer. <i>Diagnostic Pathology</i> , 2019, 14, 33.	2.0	7
81	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. <i>Pathology and Oncology Research</i> , 2020, 26, 2709-2722.	1.9	7
82	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. <i>BioMed Research International</i> , 2020, 2020, 1-13.	1.9	7
83	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours. <i>Biomedicines</i> , 2021, 9, 1831.	3.2	7
84	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. <i>Experimental and Molecular Pathology</i> , 2018, 105, 50-56.	2.1	6
85	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 625-636.	2.8	6
86	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. <i>Neoplasia</i> , 2019, 21, 872-881.	5.3	5
87	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. <i>Cancer Medicine</i> , 2020, 9, 1409-1418.	2.8	5
88	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. <i>Molecular Medicine</i> , 2020, 26, 24.	4.4	5
89	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. <i>Pathology</i> , 2020, 52, 421-430.	0.6	5
90	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. <i>Oncotarget</i> , 2019, 10, 4973-4986.	1.8	5

#	ARTICLE	IF	CITATIONS
91	VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 8591-8606.	4.1	4
92	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. <i>BMC Cancer</i> , 2019, 19, 944.	2.6	4
93	Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. <i>Prostate</i> , 2019, 79, 302-311.	2.3	4
94	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. <i>Disease Markers</i> , 2020, 2020, 1-10.	1.3	4
95	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers. <i>International Journal of Cancer</i> , 2020, 147, 575-583.	5.1	4
96	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. <i>PeerJ</i> , 2021, 9, e11905.	2.0	4
97	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. <i>Oncotarget</i> , 2019, 10, 7096-7111.	1.8	4
98	Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology. <i>Human Pathology</i> , 2022, 126, 108-120.	2.0	4
99	High concordance of TMPRSS2-ERG fusion between primary prostate cancer and its lymph node metastases. <i>Oncology Letters</i> , 2018, 16, 6238-6244.	1.8	3
100	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 128.	1.9	3
101	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 605.e1-605.e8.	1.6	3
102	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. <i>World Journal of Urology</i> , 2021, 39, 829-837.	2.2	3
103	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. <i>Cancer Biology and Medicine</i> , 2019, 16, 319.	3.0	2
104	A nuclear shift of GSK3 β protein is an independent prognostic factor in prostate cancer. <i>Oncotarget</i> , 2019, 10, 1729-1744.	1.8	2
105	Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma. <i>Diagnostics</i> , 2021, 11, 2351.	2.6	2
106	Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2879-2884.	2.5	1
107	Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. <i>International Journal of Immunopathology and Pharmacology</i> , 2022, 36, 039463202211065.	2.1	1
108	Abstract 2833: Mesothelin expression in human tumor types: a tissue microarray study on more than 13,000 tumor samples. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
109	Abstract 2775: PD-L1 expression in human tumors: a tissue microarray study on 5,561 tissue samples and 87 tumor types. , 2021, , .		0